-
FDA approves new indication for Genentech’s Lucentis
SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Genentech’s Lucentis (ranibizumab injection). The drug has been approved to treat patients with myopic choroidal neovascularization, which is a complication of severe near-sightedness that can lead to blindness.OncoGenex to acquire Achieve Life Science
BOTHEL, Wash., and VANCOUVER, British Columbia — OncoGenex Pharmaceuticals will acquire Achieve Life Science in all-stock transaction. OncoGenex is a publicly traded oncology biopharmaceutical company, while Achieve is a privately held specialty pharmaceutical provider.
Under terms of the agreement, expected to close in mid-2017, Achieve’s shareholders will own 75 percent of the combined company, while OncoGenex shareholders will own the remaining 25 percent.